Prentice Ann, Bonjour Jean-Philippe, Branca Francesco, Cooper Cyrus, Flynn Albert, Garabedian Michèle, Müller Detlef, Pannemans Daphne, Weber Peter
MRC Human Nutrition Research, Elsie Widdowson Laboratory, Fulbourn Road, Cambridge CB1 9NL, UK.
Eur J Nutr. 2003 Mar;42 Suppl 1:I28-49. doi: 10.1007/s00394-003-1103-1.
The EC Concerted Action PASSCLAIM aims to produce a generic tool for assessing the scientific support for health-related claims for foods and food components.
The task of the ITGB Working Group was to critically evaluate the categories of scientific evidence needed to support claims in relation to bone health and osteoporosis.
A framework was developed to describe the chain of evidence that is required to link the consumption of a food or food component to bone health outcomes. Techniques available for interrogating each link in the chain were identified and their strengths and weaknesses considered. This framework was used to determine intermediate markers of health outcome with respect to osteoporosis and to debate the level of evidence that would be required to substantiate claims of enhanced function or reduced disease risk.
Use of this framework with osteoporotic fracture as the health endpoint resulted in the following judgements based on current knowledge: 1) bone mineral density (BMD) is an intermediate marker of bone health which, for people of any age and sex, can provide evidence of enhanced function; 2) for people over 50 years living in populations with a high incidence of fracture, BMD is an intermediate marker of osteoporotic fracture risk which can provide evidence of an increased probability of reduced disease risk; 3) because osteoporosis is defined as a state of increased fracture risk due to low bone mass and deterioration in bone microarchitecture, a claim of a definite reduction in osteoporosis or fracture risk requires similar substantiation to claims that fractures are prevented or treated, including clinical trials and animal studies; 4) data from lower in the chain of evidence, such as bone turnover and calcium bioavailability, are not, by themselves, sufficiently strongly related to bone health endpoints to provide evidence of enhanced function or reduced disease risk but can provide supporting information.
In the light of existing scientific knowledge, a framework has been developed as a tool for considering the scientific support for claims relating to bone health and osteoporosis. To provide a working example, the framework has been used to assess the current position with osteoporotic fracture as the health endpoint. This experience will contribute to the formulation under PASSCLAIM of a generic tool for assessing the scientific support of health claims on foods.
欧盟联合行动PASSCLAIM旨在开发一种通用工具,用于评估食品及食品成分健康声称的科学依据。
ITGB工作组的任务是严格评估支持与骨骼健康和骨质疏松症相关声称所需的科学证据类别。
制定了一个框架,以描述将食品或食品成分的摄入与骨骼健康结果联系起来所需的证据链。确定了可用于审查证据链中每个环节的技术,并考虑了其优缺点。该框架用于确定与骨质疏松症相关的健康结果中间标志物,并讨论证实功能增强或疾病风险降低声称所需的证据水平。
以骨质疏松性骨折作为健康终点使用该框架,根据现有知识得出以下判断:1)骨矿物质密度(BMD)是骨骼健康的中间标志物,对于任何年龄和性别的人,都可提供功能增强的证据;2)对于生活在骨折高发人群中的50岁以上人群,BMD是骨质疏松性骨折风险的中间标志物,可提供疾病风险降低可能性增加的证据;3)由于骨质疏松症被定义为由于骨量低和骨微结构恶化导致骨折风险增加的状态,明确降低骨质疏松症或骨折风险的声称需要与预防或治疗骨折的声称类似的证据支持,包括临床试验和动物研究;4)证据链中较低层次的数据,如骨转换和钙生物利用度,本身与骨骼健康终点的相关性不够强,无法提供功能增强或疾病风险降低的证据,但可提供支持性信息。
根据现有科学知识,已开发出一个框架作为工具,用于考虑与骨骼健康和骨质疏松症相关声称的科学依据。为提供一个实际示例,该框架已用于以骨质疏松性骨折作为健康终点评估当前状况。这一经验将有助于在PASSCLAIM下制定一种通用工具,用于评估食品健康声称的科学依据。